Table 2 |
||||||||
|
Summary of included case-control studies and characteristics |
||||||||
|
Study, Year, Country |
Subjects |
Mean age (year) |
Mean duration (year) |
Type of bisphosphonate |
AF definition |
Total AF events (n) |
Variables matched and/or controlled |
Quality assessment score§ |
|
|
||||||||
|
Heckbert and colleagues [7], 2008, USA |
1,685 women in a commercial health care system database |
73 |
20 |
Alendronate |
ICD-9 codes verified by medical records +/- EKG |
719 |
Age, HTN, calendar year, osteoporosis, and any cardiovascular disease |
4/2/3 |
|
Sorensen and colleagues [19], 2008, Denmark |
81,640 women in the National Registry of Patients |
>75 |
Not reported |
Alendronate Etidronate |
ICD-8 and 10 codes |
13586 |
Age, county, cardiovascular disease, renal failure, DM, HRT, fracture, cancer, alcoholism, pulmonary disease, anti-thyroid drugs, osteoporosis, steroid use, etc |
3/2/3 |
|
Grosso and colleagues* [16], 2009, UK |
2,195 women with AF in the UK General Practice Research Database |
82 |
13 |
Alendronate Risedronate |
Diagnosis codes and Read codes |
2195 |
Age+ |
3/2/3 |
|
Levesque and colleagues [18], 2009, Canada |
63,843 adults (BIS users and raloxifene users) in the Quebec health database |
75 |
4 |
Alendronate Etidronatea Risedronatea |
Not reported |
2149 |
Age, cohort entry year, follow-up, CAD, HTN, and use of HRT |
N/A |
|
|
||||||||
|
AF, atrial fibrillation; BIS, bisphosphonates; CAD, coronary artery disease; DM, diabetes mellitus; EKG, electrocardiogram; HRT, hormone replacement therapy; HTN, hypertension; ICD, International Classification of Diseases. * self-controlled case-series. + no other adjustment not needed in self-controlled study, N/A, not applicable (only the abstract was available at the time of this study), a risks specific to etidronate or risedronate not used in meta-analysis, § Methodologic quality assessment score based on Newcastle-Ottawa Scale [23]; selection (0 to 4), comparability (0 to 2), and outcome score (0 to 3) points with a higher score representing a better quality. |
||||||||
|
Kim et al. Arthritis Research & Therapy 2010 12:R30 doi:10.1186/ar2938 |
||||||||
